Skip to Main Content

Just 12% of the 162,000 people estimated to be living with cystic fibrosis in nearly 100 countries are receiving a highly effective, but pricey treatment. And tens of thousands more are believed to be undiagnosed in dozens of other countries where the medicine is not available, according to a new study.

The findings suggest a sizable global disparity in treating cystic fibrosis, an inherited disorder that severely damages the lungs and limits life expectancy to 46 years in the U.S., according to the Cystic Fibrosis Foundation. The average life expectancy has climbed from 38 years a decade ago, due in part to the recent arrival of new medicines. But life expectancy can be half as much in low and middle-income countries, notably many in Africa.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment